Jin X#, Zhou YF#, Ma D#, Zhao S#, Lin CJ#, Xiao Y, Fu T, Liu CL., Chen YY, Xiao WX, Liu YQ, Chen QW, Yu Y, Shi LM, Shi JX., Huang W, Robertson JFR., Jiang YZ*, Shao ZM*. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023 Oct;55(10): 1696-1708.
Xiao Y, Yu TJ, Xu Y, Ding R, Wang YP, Jiang YZ, Shao ZM*. Emerging therapies in cancer metabolism. Cell Metab.2023 Aug 8;35(8):1283-1303.
Liu Y#, Zhu XZ#, Xiao Y#, Wu SY#, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ*, Wang ZH*, Shao ZM*. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell Res. 2023 May;33(5):389-402.
Yang F#, Xiao Y#, *, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ*, Shao ZM*. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023 Jan 08;35(1):84-100.e8.
